Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07528196 | Study of Xuanbai Shengmai Decoction in the Treatment of Acute Respiratory Distress Syndrome | PHASE3 | NOT YET_RECRUITING | 308 | — | — | Aug 20, 2026 | Dec 1, 2027 | Jun 5, 2026 | - | — |
Mortality was calculated on day 28 of treatment.
| Arm | Type | Description |
|---|---|---|
| Control Group | NO_INTERVENTION | Patients in the control group will receive standard comprehensive Western medical treatment. |
| Treatment Group | EXPERIMENTAL | Patients in the treatment group will receive Xuanbai Shengmai Decoction via oral administration or nasogastric feeding on the basis of standard comprehensive Western medical treatment. The decoction will be administered within 24 hours after enrollment, one dose per day divided into two administrations, for a total treatment duration of 7 days. |
| Name | Type | Description |
|---|---|---|
| Xuanbai Shengmai Decoction | DRUG | Patients in the treatment group will receive Xuanbai Shengmai Decoction orally or via nasogastric gavage on the basis of standard comprehensive Western medical treatment. The decoction will be administered within 24 hours after enrollment, one dose per day in two divided administrations, for a total of 7 days. |
Inclusion Criteria: 1. Met the diagnostic criteria for ARDS according to the 2023 updated global definition. 2. Within 48 hours of meeting the diagnostic criteria. 3. Aged ≥ 18 years and ≤ 85 years. Exclusion Criteria: 1. Did not meet the diagnostic criteria. 2. Pregnant or lactating women. 3. Pa...